Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alma Franceschini"'
Autor:
Serena Mazzucchelli, Lorena Signati, Letizia Messa, Alma Franceschini, Arianna Bonizzi, Lorenzo Castagnoli, Patrizia Gasparini, Clarissa Consolandi, Eleonora Mangano, Paride Pelucchi, Ingrid Cifola, Tania Camboni, Marco Severgnini, Laura Villani, Barbara Tagliaferri, Stephana Carelli, Serenella M. Pupa, Cristina Cereda, Fabio Corsi
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Background A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy
Externí odkaz:
https://doaj.org/article/87a0c667c3c14d669d41b5cdc4ebd64b
Autor:
Lorenzo Castagnoli, Simona Corso, Alma Franceschini, Alessandra Raimondi, Sara Erika Bellomo, Matteo Dugo, Federica Morano, Michele Prisciandaro, Silvia Brich, Antonino Belfiore, Andrea Vingiani, Maria Di Bartolomeo, Giancarlo Pruneri, Elda Tagliabue, Silvia Giordano, Filippo Pietrantonio, Serenella M. Pupa
Publikováno v:
Cellular Oncology. 46:661-676
Purpose Trastuzumab is an HER2-specific agent approved as the gold-standard therapy for advanced HER2-positive (HER2+) gastric cancer (GC), but the high rate and rapid appearance of resistance limit its clinical efficacy, resulting in the need to ide
Autor:
Francesca Ligorio, Serenella M. Pupa, Valeria Cancila, Alma Franceschini, Lorenzo Castagnoli, Claudio Tripodo, Claudio Vernieri
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4778, p 4778 (2021)
Cancers, Vol 13, Iss 4778, p 4778 (2021)
Simple Summary Breast cancer (BC) is not a single disease, but a group of different tumors, and altered HER2 expression defines a particularly aggressive subtype. Although HER2 pharmacological inhibition has dramatically improved the prognosis of HER